THOUSAND OAKS, Calif. and
LOUISVILLE, Ky., Aug. 17, 2017 /PRNewswire/ -- Two of the
nation's leading health organizations, health and well-being
company Humana Inc. (NYSE: HUM) and biotechnology company Amgen
(NASDAQ:AMGN), have teamed up to identify opportunities to improve
health outcomes and improve efficiency by unlocking new insights
from the real world health care experiences of Humana's 13 million
members.
In the collaboration agreement between Amgen and Humana, six
projects are currently underway or planned, with more expected over
the term of the agreement. Both organizations are committed to
expanding the work into further therapeutic areas where the
partnership can bring value to both Amgen and Humana. The goal is
the same across all projects: deliver increased value to patients
and the health care system by focusing on working to improve
quality and outcomes in the context of total health care costs.
The collaboration will initially target multiple serious
conditions, including cardiovascular disease, osteoporosis,
neurologic disorders, inflammatory diseases and cancer. Researchers
will combine available sources of real world evidence (RWE) with
data from wearable technology, digital apps and Bluetooth-enabled
drug delivery devices. Prospective observational studies are also
planned.
Planned research will identify patients whose serious medical
conditions are likely to result in an adverse patient outcome,
which may lead to development of algorithms that can predict risk
and drive to early intervention. The partnership will also dive
deeply into specific therapeutic areas, from defining the burden of
osteoporatic fractures to understanding the impact of wearable
technology on medication adherence for inflammatory diseases.
"The rising cost of disease is challenging the sustainability of
our health care system in the U.S., and is motivating innovators to
urgently develop new therapeutic options and partner on
opportunities to improve the quality and efficiency of care and
reduce financial burden to the system," said Joshua Ofman, M.D., M.S.H.S., senior vice
president of Global Value, Access & Policy at Amgen. "It is our
hope that this collaboration with Humana, a first of its kind
for Amgen, will cultivate value-based, integrated approaches to
care that will focus on patients and benefit the healthcare system
more broadly."
"Humana is focused on the holistic health of our members and by
teaming up with Amgen we can study new ways to improve the health
outcomes for our members," said Laura
Happe, Pharm.D. M.P.H., chief pharmacy officer for Humana.
"At the same time, we hope this research results in new tools and
technology that support our provider partners who are on the
journey to population health and value-based care."
Amgen and Humana have proven experience in value-based
initiatives. Globally, Amgen has engaged in more than 75 distinct
value-based programs that have focused on improving clinical
outcomes, patient experience and population health.
As of June 30, 2017, Humana has
1.8 million individual Medicare Advantage members and 142,000
commercial members who are cared for by 50,700 primary care
providers, in more than 900 value-based relationships across 43
states and Puerto Rico. By
focusing on quality and health, Humana experienced 20 percent lower
costs in total in 2015 for members who were treated by providers in
a value-based reimbursement model setting versus an estimation of
original fee-for-service Medicare costs using CMS Limited Data Set
Files.
About Amgen
Amgen is committed to unlocking
the potential of biology for patients suffering from serious
illnesses by discovering, developing, manufacturing, and delivering
innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease
and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
Amgen and Value-Based Programs
As a collaborative
partner within the healthcare system, Amgen believes that engaging
in value-based programs with stakeholders creates mutually
beneficial opportunities to improve costs, quality of care and the
patient experience.
Globally, Amgen is engaged in over 75 distinct, value-based
projects, spanning disease state collaborations, risk sharing,
cost-cap guarantee, pay-for-performance and outcomes-based
agreements.
About Humana
Humana Inc. is committed to helping our
millions of medical and specialty members achieve their best
health. Our successful history in care delivery and health plan
administration is helping us create a new kind of integrated care
with the power to improve health and well-being and lower costs.
Our efforts are leading to a better quality of life for people with
Medicare, families, individuals, military service personnel, and
communities at large.
To accomplish that, we support physicians and other health care
professionals as they work to deliver the right care in the right
place for their patients, our members. Our range of clinical
capabilities, resources and tools – such as in-home care,
behavioral health, pharmacy services, data analytics and wellness
solutions – combine to produce a simplified experience that makes
health care easier to navigate and more effective.
More information regarding Humana is available to investors via
the Investor Relations page of the company's web site at
www.humana.com, including copies of:
- Annual reports to stockholders
- Securities and Exchange Commission filings
- Most recent investor conference presentations
- Quarterly earnings news releases and conference calls
- Calendar of events
- Corporate Governance information
CONTACT:
Amgen, Thousand Oaks
Kristen
Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060
(investors)
Humana
Marina Renneke,
602-760-1758, mrenneke@humana.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency-300506215.html
SOURCE Amgen